Cargando…

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression

Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder (MDD), yet their mechanisms of action are not fully understood and their therapeutic benefit varies among individuals. We used a targeted metabolomics approach utilizing a panel of 180 metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales:	MahmoudianDehkordi, Siamak, Ahmed, Ahmed T., Bhattacharyya, Sudeepa, Han, Xianlin, Baillie, Rebecca A., Arnold, Matthias, Skime, Michelle K., John-Williams, Lisa St., Moseley, M. Arthur, Thompson, J. Will, Louie, Gregory, Riva-Posse, Patricio, Craighead, W. Edward, McDonald, William, Krishnan, Ranga, Rush, A. John, Frye, Mark A., Dunlop, Boadie W., Weinshilboum, Richard M., Kaddurah-Daouk, Rima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925685/ https://www.ncbi.nlm.nih.gov/pubmed/33654056 http://dx.doi.org/10.1038/s41398-020-01097-6

Ejemplares similares

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety—A Role for Bile Acids
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2022)

Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
por: Brydges, Christopher R., et al.
Publicado: (2021)

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
por: Joyce, Jeremiah B., et al.
Publicado: (2021)

Rise of escitalopram and the fall of citalopram
por: Cavanah, Luke R., et al.
Publicado: (2023)

Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression
por: Nho, Kwangsik, et al.
Publicado: (2021)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

The Metabolome-Wide Signature of Major Depressive Disorder
por: Jansen, Rick, et al.
Publicado: (2023)

Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study
por: Qirjazi, Elena, et al.
Publicado: (2016)

Prediction of Ventricular Arrhythmias by QRS/QTc - Ratio in Citalopram or Escitalopram Intoxication
por: Dietrichs, Erik Sveberg, et al.
Publicado: (2022)

Assessment of citalopram and escitalopram on neuroblastoma cell lines: Cell toxicity and gene modulation
por: Sakka, Laurent, et al.
Publicado: (2017)

Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data
por: de Bardeci, Mateo, et al.
Publicado: (2022)

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
por: Nho, Kwangsik, et al.
Publicado: (2019)

Micelle Enhanced Fluorimetric and Thin Layer Chromatography Densitometric Methods for the Determination of (±) Citalopram and its S – Enantiomer Escitalopram
por: Taha, Elham A., et al.
Publicado: (2009)

Effect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline
por: Gjestad, Caroline, et al.
Publicado: (2015)

Peripheral serum metabolomic profiles inform central cognitive impairment
por: Wang, Jingye, et al.
Publicado: (2020)

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants
por: Alkhafaji, Ali A, et al.
Publicado: (2012)

ERICH3: vesicular association and antidepressant treatment response
por: Liu, Duan, et al.
Publicado: (2020)

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
por: Aldrich, Stacey L., et al.
Publicado: (2019)

Double blind, randomised trial to compare efficacy of escitalopram versus citalopram for interferon induced depression in hepatitis C patients
por: Shakeel, Uzma, et al.
Publicado: (2020)

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
por: Lalit, Vaya, et al.
Publicado: (2004)

Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population‐based cohort study in older adults
por: Aakjær, Mia, et al.
Publicado: (2022)

Acylcarnitine Profiles in Acetaminophen Toxicity in the Mouse: Comparison to Toxicity, Metabolism and Hepatocyte Regeneration
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2013)

Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts
por: St. John-Williams, Lisa, et al.
Publicado: (2019)

Plasma acylcarnitine concentrations reflect the acylcarnitine profile in cardiac tissues
por: Makrecka-Kuka, Marina, et al.
Publicado: (2017)

Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
por: Faraj, Pari, et al.
Publicado: (2023)

Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
por: Arnold, Matthias, et al.
Publicado: (2020)

The significance of acylcarnitine ratio indices in diagnosing carnitine-acylcarnitine translocase deficiency
por: Shi, Congcong, et al.
Publicado: (2023)

Acylcarnitine ratio indices in diagnosing carnitine-acylcarnitine translocase deficiency in newborns
por: Tan, Yifei, et al.
Publicado: (2023)

Metabolic Profiling of Patients with Schizophrenia
por: Kaddurah-Daouk, Rima
Publicado: (2006)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study
por: Abulseoud, Osama A, et al.
Publicado: (2013)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

NMR Characterization of Long-Chain Fatty Acylcarnitine Binding to the Mitochondrial Carnitine/Acylcarnitine Carrier
por: Zhang, Ningning, et al.
Publicado: (2022)

Validated Densitometric TLC-Method for the Simultaneous Analysis of (R)- and (S)-Citalopram and its Related Substances Using Macrocyclic Antibiotic as a Chiral Selector: Application to the Determination of Enantiomeric Purity of Escitalopram
por: Soliman, Suzan Mahmoud
Publicado: (2012)

The use of citalopram for the treatment of cataplexy()
por: Fonseca, Hassana de Almeida, et al.
Publicado: (2014)

Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
por: Tai, Hua-Hsin, et al.
Publicado: (2021)

Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
por: Dunlop, Boadie W.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iba18jlluevgtrkjntc2pqrn4l